Storia in 3 fonti

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

Raccontata da

asia.nikkei.com

scmp.com

caixinglobal.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

scmp.comStai leggendo2 g fa

China AI drug-design deals swell as US scrutiny mounts

Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.

originale

asia.nikkei.com2 g fa

Takeda and Insilico strike AI-led drug discovery deal worth up to $600m

Collaboration underlines surge in cross-border biotech licensing agreements

Leggi questa versione → originale

caixinglobal.com1 g fa

CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad

Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink

Leggi questa versione → originale

Timeline cronologica

giovedì 2 luglio 2026·asia.nikkei.com
Takeda and Insilico strike AI-led drug discovery deal worth up to $600m
Collaboration underlines surge in cross-border biotech licensing agreements
giovedì 2 luglio 2026·scmp.com
China AI drug-design deals swell as US scrutiny mounts
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
venerdì 3 luglio 2026·caixinglobal.com
CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing a rethink